US Stock Insider Trading | Oncolytics Biotech Discloses 11 Insider Transactions on February 13

K-LinePoet · 2026-03-12T04:38:33+00:00

February 13, 2026, Oncolytics Biotech disclosed multiple insider transactions, including Director Seizinger Bernd R. purchasing 60,000 shares on February 12. The company is dedicated to developing the immunotherapy agent pelareorep, aimed at enhancing the immune system's ability to fight cancer.

K-LinePoet

2026-03-12 04:38:33

Abstract generation in progress

Oncolytics Biotech (ONCY) disclosed 11 insider trades on February 13, 2026. Director Seizinger Bernd R. bought 60,000 shares on February 12, 2026.

【Recent Insider Trades】

Disclosure Date	Position	Name	Trade Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 13, 2026	Executive	Hagerman Allison	February 12, 2026	Buy	10,000	0.83	8,298.00
February 13, 2026	Director	Seizinger Bernd R.	February 11, 2026	Buy	60,000	0.83	49,600
February 13, 2026	Director	Pisano Wayne	February 12, 2026	Buy	30,000	0.84	25,300
February 13, 2026	Director	Seizinger Bernd R.	February 12, 2026	Buy	40,000	0.85	33,900
February 13, 2026	Director	Brown Deborah Margaret	February 12, 2026	Buy	25,000	0.85	21,200
February 13, 2026	Director	Andrews Patricia S	February 12, 2026	Buy	35,400	0.86	30,300
February 13, 2026	Director	Kelly Jared	February 11, 2026	Buy	5,600	0.84	4,681.60
February 13, 2026	Director	Kelly Jared	February 12, 2026	Buy	29,500	0.84	24,800
February 13, 2026	Executive	Aromando Andrew	February 11, 2026	Buy	29,600	0.86	25,400
February 13, 2026	Executive	Look Kirk	February 12, 2026	Buy	12,000	0.84	10,100

【Company Profile】

Oncolytics Biotech Inc. was incorporated on April 2, 1998, under Alberta law as Alberta Limited Liability Company. The company is a clinical-stage biopharmaceutical company developing pelareorep, a safe and well-tolerated intravenous immunotherapy that activates both innate and adaptive immune systems and weakens tumor defenses. This enhances the immune system’s ability to fight cancer, making tumors more susceptible to a broad range of tumor therapies.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.